- BYPHAR raw materials will be available from July 2026 in three grades: Explore (non‑GMP), Enhance (GMP) and Excel (LBLE critical raw materials produced under GMP).
- Co‑branded products are supplied via partnerships with Budenheim, Citribel, K+S and Kerry.
- Noted raw substances include high‑purity phosphates, citric acid and citrates, pharmaceutical‑grade NaCl and KCl, and acetates.
- The portfolio targets manufacturing processes such as mAbs, recombinant proteins, cell and gene therapies, vaccines, nucleic‑acid production and ADCs.
Overview
Brenntag unveiled BYPHAR, a biopharma product range that consolidates raw materials and services to support manufacturing from early development through commercial production.
Product grades and availability
The range will be offered from July 2026 in three grades: BYPHAR Explore (non‑GMP, monograph‑compliant for early R&D), BYPHAR Enhance (GMP‑compliant, aligned with IPEC/EXCiPACT and provided with full regulatory documentation) and BYPHAR Excel (LBLE critical raw materials produced under GMP and multicompendial where applicable).
Supplier partnerships and substances
Co‑branded products are manufactured in partnership with Budenheim, Citribel, K+S and Kerry; highlighted substances include high‑purity phosphates, citric acid and citrates, pharmaceutical‑grade NaCl and KCl, and acetates.
Applications and customers
The portfolio is intended for mAbs, recombinant proteins, cell & gene therapies, vaccines, nucleic‑acid production (mammalian and microbial), ADC manufacturing and aims to serve innovators, emerging biotech, CDMOs, vaccine and biosimilar producers, and diagnostic companies.
Regulatory and supply
Materials are provided with regulatory‑ready documentation and are supported by Brenntag’s global distribution network and technical capabilities to address supply, documentation consistency and compliance.
